With pending news between now and July sometime on CRUISE I Data and likely licensing deal(s), I like my chances for appreciation. Calcitriol and dosing completed on CRUISE II soon followed by data. New drug (SFP) app. with potential for fast FDA review due to excellent safety and better outcomes later this year. Add in more sales of core products and leverage those sales with new products, 2013 is very promising.
They had a lot of "run up" traders trying to pump this one, but still didn't really move.. I think it's going to take some kind of big news to get this one going.. I was hoping this would run close to $5 by the time results came out.. We might see a little bit of a pullback in the next few weeks as the "run up" traders will all sell towards the end of June